Not sure why Insmed would "lose autonomy" for decision making about which indications to develop. Optimally, whatever partner they choose, (and at this point I believe Insmed has several to choose from), will allow the science to drive development. Any partner that would take away that initiative would obviously be a poor choice.
I think the management at Insmed have demonstrated the savvy to make a good choice in a partner by having gotten their drug FDA approved in the face of otherwise withering opposition from TRCA and DNA...
A partner would, I believe, simply bring a fat wallet to the table. And I have NO problem with that scenario.. do you?
Market Data 
Markets 
AI
